Why scientists are deliberately infecting volunteers with covid-19

If you are going to catch covid-19, jokes Jacob Hopkins, a university student, the safest place to do it is in a hospital. So in March Mr Hopkins lay down on a bed in the Royal Free Hospital in London while doctors placed droplets of liquid carrying the sarscov-2 virus into his nose. Mr Hopkins was one of 36 participants in the first “human challenge trial” (hct) for covid-19.

Human trials are a valuable part of medical research. Studying sick people in the controlled environment of a lab allows scientists to collect valuable information about how diseases work much more quickly than relying on messy and uncertain data from the real world.

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Open Orphan Plc

More articles like this

Open Orphan Plc

What is RSV in babies?

Respiratory Syncytial Virus, commonly referred to as RSV, is a respiratory virus that causes cold-like symptoms in the typical healthy adult, which can last on average for one week. However, RSV in the elderly, babies and young children

Open Orphan Plc

Medical writing & regulatory affairs

From the early phases of development through marketing authorisation, regulatory interactions are essential to your progress and success. These exchanges will not only shape the advancement of your program, but also the value of your asset and your

Open Orphan Plc

Open Orphan positive results emerge from RSV Human Challenge Study

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials, has noted the announcement dated 1 September 2021 from Barvarian Nordic

Open Orphan Plc

The man who chose to get Covid

Jake Hopkins, a university student in the U.K., decided earlier this year to do something most people in the world have been trying to avoid: he volunteered to get Covid-19. Jake signed up for a human challenge trial

Open Orphan Plc

Open Orphan wins €9.5m asthma contract with major pharma company

Dublin-listed pharmaceutical services company Open Orphan said its subsidiary hVivo has signed an £8.1 million (€9.5 million) asthma contract with a major pharmaceutical firm to test an inhaled human rhinovirus antiviral product. Around 5.4 million people in the